Table 6.
Univariate Cox regression model of clinical parameters on disease specific survival in stratified high-grade serous carcinoma (HGSC)
| All HGSC | Advanced stage HGSC | Poor prognosis HGSC | Low Stage HGSC | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard | 95.0% CI | Hazard | 95.0% CI | Hazard | 95.0% CI | Hazard | 95.0% CI | |||||||||||||
| Ratio | Lower | Upper | n | p value | Ratio | Lower | Upper | n | p value | Ratio | Lower | Upper | n | p value | Ratio | Lower | Upper | n | p value | |
| BRCA mutation carrier statusa | ||||||||||||||||||||
| Non carrier | 351 | reference | 293 | reference | 236 | reference | 61 | reference | ||||||||||||
| BRCA1 carrier | 0.62 | 0.44 | 0.88 | 67 | 0.007 | 0.65 | 0.44 | 0.95 | 45 | 0.029 | 0.79 | 0.51 | 1.20 | 32 | 0.268 | 0.92 | 0.40 | 2.11 | 21 | 0.849 |
| BRCA2 carrier | 0.42 | 0.24 | 0.72 | 34 | 0.002 | 0.41 | 0.22 | 0.76 | 26 | 0.004 | 0.39 | 0.20 | 0.77 | 21 | 0.006 | 0.80 | 0.19 | 3.44 | 7 | 0.766 |
| All mutated vs no mutation | 0.56 | 0.42 | 0.76 | 472 | 0.000 | 0.57 | 0.41 | 0.80 | 375 | 0.001 | 0.64 | 0.44 | 0.93 | 294 | 0.02 | 0.82 | 0.37 | 1.81 | 85 | 0.78 |
| Chemotherapy treatment type | ||||||||||||||||||||
| Carboplatinum+taxane | 940 | reference | 727 | reference | 469 | reference | 167 | reference | ||||||||||||
| Cisplatinum+taxane | 1.14 | 0.87 | 1.50 | 71 | 0.348 | 0.63 | 0.44 | 0.89 | 67 | 0.728 | 1.11 | 0.83 | 1.49 | 60 | 0.495 | NA | NA | NA | 4 | NA |
| Platinum | 1.86 | 1.37 | 2.52 | 63 | 0.000 | 0.42 | 0.24 | 0.73 | 46 | 0.000 | 2.65 | 1.83 | 3.83 | 38 | 0.000 | 1.65 | 0.71 | 3.84 | 13 | 0.245 |
| Platinum+other | 1.93 | 1.35 | 2.75 | 38 | 0.000 | 0.56 | 0.42 | 0.76 | 33 | 0.005 | 1.44 | 0.94 | 2.19 | 28 | 0.093 | NA | NA | NA | 3 | NA |
| Provinces | ||||||||||||||||||||
| Quebec | 584 | reference | 472 | reference | 275 | reference | Lower | Upper | NA | |||||||||||
| Ontario | 0.80 | 0.66 | 0.98 | 195 | 0.034 | 0.69 | 0.54 | 0.88 | 119 | 0.003 | 0.77 | 0.58 | 1.03 | 89 | 0.074 | NA | NA | NA | NA | NA |
| Alberta | 0.71 | 0.56 | 0.91 | 120 | 0.007 | 0.73 | 0.56 | 0.96 | 88 | 0.025 | 0.51 | 0.34 | 0.78 | 41 | 0.002 | NA | NA | NA | NA | NA |
| Manitoba | 0.46 | 0.15 | 1.45 | 10 | 0.185 | 0.20 | 0.03 | 1.45 | 7 | 0.111 | NA | NA | NA | 6 | NA | NA | NA | NA | NA | NA |
| British Columbia | 0.99 | 0.84 | 1.17 | 307 | 0.917 | 1.02 | 0.86 | 1.21 | 248 | 0.841 | 1.21 | 0.99 | 1.47 | 210 | 0.064 | NA | NA | NA | NA | NA |
Bold values highlights the statistically significant difference with the reference category
NA non applicable, number of cases too low, n number of patients with follow-up, HR Hazard ratio
a platinum-based patients only, low stage: disease stage I and II, advanced stage: disease stage III and IV